发明名称 |
TREATMENT OF MULTIPLE SCLEROSIS BY ALEMTUZUMAB INDUCTION FOLLOWED BY LAQUINIMOD THERAPY |
摘要 |
This invention provides a method of treating a subject afflicted with multiple sclerosis (MS) or presenting clinically isolated syndrome (CIS) which comprises a) administering to the subject an amount of an anti-CD52 antibody, followed by b) periodically administering to the subject an amount of laquinimod. This invention also provides packages comprising pharmaceutical compositions of laquinimod or an anti-CD52 antibody for treating such a subject wherein laquinimod is to be administered as a maintenance therapy in such a subject who has received an anti-CD52 antibody induction therapy. |
申请公布号 |
EP3027187(A1) |
申请公布日期 |
2016.06.08 |
申请号 |
EP20140831822 |
申请日期 |
2014.07.31 |
申请人 |
TEVA PHARMACEUTICAL INDUSTRIES LTD. |
发明人 |
KNAPPERTZ, VOLKER |
分类号 |
A61K31/4704;A61K39/395;C07K16/28 |
主分类号 |
A61K31/4704 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|